{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:44:07Z","timestamp":1790073847983,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12149-025-02127-3","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:25:50Z","timestamp":1762496750000},"page":"298-309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of Lutetium-177 (177Lu)-PSMA-617 in metastatic Castration-Resistant prostate cancer patients with superscan pattern: A retrospective cohort study"],"prefix":"10.1007","volume":"40","author":[{"given":"Amirreza","family":"Shamshirgaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Sahafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hadi","family":"Samadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadis","family":"Mohammadzadeh Kosari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheila","family":"Erfani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe","family":"Pirayesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Aryana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Harsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emran","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"issue":"1","key":"2127_CR1","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2127_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63\u201389.","journal-title":"World J Oncol"},{"issue":"11","key":"2127_CR3","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180\u201392.","journal-title":"Int J Clin Pract"},{"issue":"12","key":"2127_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"22","key":"2127_CR5","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091\u2013102.","journal-title":"N Engl J Med"},{"issue":"1","key":"2127_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Sch\u00e4fers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85\u201390.","journal-title":"J Nucl Med"},{"issue":"12","key":"2127_CR7","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","volume":"46","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46(12):2536\u201344.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10276","key":"2127_CR8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804.","journal-title":"Lancet"},{"issue":"6","key":"2127_CR9","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209(6):1082\u201390.","journal-title":"J Urol"},{"key":"2127_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14192229","volume":"14","author":"E Askari","year":"2024","unstructured":"Askari E, Shakeri S, Roustaei H, Fotouhi M, Sadeghi R, Harsini S, et al. Superscan pattern on bone scintigraphy: a comprehensive review. Diagnostics. 2024;14:19.","journal-title":"Diagnostics"},{"issue":"13","key":"2127_CR11","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235\u201346.","journal-title":"N Engl J Med"},{"issue":"11","key":"2127_CR12","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.2967\/jnumed.124.267816","volume":"65","author":"V Murthy","year":"2024","unstructured":"Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, et al. Efficacy and toxicity of [(177)Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer: results from the U.S. expanded-access program and comparisons with phase 3 VISION data. J Nucl Med. 2024;65(11):1740\u20134.","journal-title":"J Nucl Med"},{"issue":"2","key":"2127_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","volume":"87","author":"S Gillessen","year":"2025","unstructured":"Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, et al. Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2025;87(2):157\u2013216.","journal-title":"Eur Urol"},{"issue":"12","key":"2127_CR14","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402\u201318.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2127_CR15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1159\/000503095","volume":"12","author":"F Azam","year":"2019","unstructured":"Azam F, Latif MF, Farooq A, Tirmazy HS, AlShahrani S, Bashir S, et al. Performance status assessment by using ECOG (eastern cooperative oncology group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol. 2019;12(3):728\u201336.","journal-title":"Case Rep Oncol"},{"key":"2127_CR16","unstructured":"Radiation Protection and Safety in Medical Uses of Ionizing Radiation. Vienna: INTERNATIONAL ATOMIC ENERGY AGENCY; 2018."},{"key":"2127_CR17","unstructured":"Institute NC. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc. htm. 2009."},{"issue":"6","key":"2127_CR18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2967\/jnumed.119.236414","volume":"61","author":"J Violet","year":"2020","unstructured":"Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of (177)Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61(6):857\u201365.","journal-title":"J Nucl Med"},{"issue":"1","key":"2127_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clgc.2018.09.014","volume":"17","author":"L Emmett","year":"2019","unstructured":"Emmett L, Crumbaker M, Ho B, Willowson K, Eu P, Ratnayake L. Results of a prospective phase 2 pilot trial of 177Lu\u2013PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression. Clin Genitourin Cancer. 2019;17(1):15\u201322.","journal-title":"Clin Genitourin Cancer"},{"key":"2127_CR20","unstructured":"Fizazi K, Chi KN, Shore ND, Herrmann K, de Bono JS, Castellano D et al. Final overall survival and safety analyses of the phase 3 PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025 Jul 16."},{"key":"2127_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164017","author":"D Groener","year":"2021","unstructured":"Groener D, Baumgarten J, Haefele S, Happel C, Klimek K, Mader N, et al. Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13164017.","journal-title":"Cancers"},{"issue":"1","key":"2127_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/RLU.0b013e3181feeb8c","volume":"36","author":"LK Harshman","year":"2011","unstructured":"Harshman LK, Latifi HR, Griffeth LK. Visualization of discrete sacral foramina as an ancillary sign of superscan. Clin Nucl Med. 2011;36(1):21\u20134.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"2127_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y","volume":"61","author":"MS Soloway","year":"1988","unstructured":"Soloway MS, Hardeman SW, Hickey D, Todd B, Soloway S, Raymond J, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61(1):195\u2013202.","journal-title":"Cancer"},{"key":"2127_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14192229","author":"E Askari","year":"2024","unstructured":"Askari E, Shakeri S, Roustaei H, Fotouhi M, Sadeghi R, Harsini S, et al. Superscan pattern on bone scintigraphy: a comprehensive review. Diagnostics. 2024. https:\/\/doi.org\/10.3390\/diagnostics14192229.","journal-title":"Diagnostics"},{"issue":"4","key":"2127_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.22551\/2023.41.1004.10267","volume":"10","author":"DF Galindo Cortes","year":"2023","unstructured":"Galindo Cortes DF, Mejia Efeer H, Caro Perdomo S, Hernandez Hidalgo N. Superscan on (68)Ga PSMA PET\/CT in patients with metastatic prostate carcinoma: a case series. Arch Clin Cases. 2023;10(4):164\u201370.","journal-title":"Arch Clin Cases"},{"key":"2127_CR26","doi-asserted-by":"crossref","unstructured":"Ng CWQ, Chua WM, Lam WW, Tong AK, Ng DCE, Tang CYL et al. Safety and efficacy of Lutetium-177 PSMA radioligand therapy in metastatic Castration-Resistant prostate cancer with diffuse bone metastases (Asian population Study). Asia Pac J Clin Oncol. 2025 May 29.","DOI":"10.1111\/ajco.14195"},{"issue":"24","key":"2127_CR27","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.2217\/fon-2018-0087","volume":"14","author":"D Heinrich","year":"2018","unstructured":"Heinrich D, Bruland \u00d8, Guise TA, Suzuki H, Sartor O. Alkaline phosphatase in metastatic Castration-Resistant prostate cancer: reassessment of an older biomarker. Future Oncol. 2018;14(24):2543\u201356. 2018\/06\/21.","journal-title":"Future Oncol"},{"issue":"13","key":"2127_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26135970","volume":"26","author":"CL Peng","year":"2025","unstructured":"Peng CL, Chen CT, Tang IC. Exploring the Therapeutic Potential of 177Lu-PSMA-617 in a Mouse Model of Prostate Cancer Bone Metastases. Int J Mol Sci. 2025;26(13):5970. https:\/\/doi.org\/10.3390\/ijms26135970.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2127_CR29","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M, Bene\u0161ov\u00e1 M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57(8):1170\u20136.","journal-title":"J Nucl Med"},{"issue":"1","key":"2127_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/RLU.0000000000002833","volume":"45","author":"MP Yadav","year":"2020","unstructured":"Yadav MP, Ballal S, Bal C, Sahoo RK, Damle NA, Tripathi M, et al. Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients. Clin Nucl Med. 2020;45(1):19\u201331.","journal-title":"Clin Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02127-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02127-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02127-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:59:40Z","timestamp":1772024380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02127-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2127"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02127-3","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}